Logo

Alvotech's AVT02 (a proposed biosimilar to Humira) Receives CHMP's Positive Opinion for the Treatment of Autoimmune Diseases

Share this
Alvotech's AVT02 (a proposed biosimilar to Humira) Receives CHMP's Positive Opinion for the Treatment of Autoimmune Diseases

Alvotech's AVT02 (a proposed biosimilar to Humira) Receives CHMP's Positive Opinion for the Treatment of Autoimmune Diseases

Shots:

  • The EMA’s CHMP has recommended the approval of Alvotech‘s AVT02 (100 mg/mL)- a proposed biosimilar to Humira (adalimumab)  to treat AD in the EU
  • The EC has been assigned to discuss the marketing authorization for AVT02. If approved- AVT02 will be extended to all EU member states along with other countries in the EEA- Iceland- Liechtenstein- and Norway
  • Adalimumab is used to treat certain inflammatory conditions. Alvotech’s pipeline contains several mAb and fusion-protein biosimilar candidates that focus on autoimmunity- oncology- and inflammatory conditions to improve QoL for patients globally

  | Ref:  Businesswire  | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions